Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

@article{Kagan2008ScreeningFT,
  title={Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.},
  author={Karl Oliver Kagan and David Wright and Nerea Maiz and Ivilina Pandeva and Kypros H. Nicolaides},
  journal={Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology},
  year={2008},
  volume={32 4},
  pages={488-92}
}
OBJECTIVES To derive a model and examine the performance of first-trimester screening for trisomy 18 by maternal age, fetal nuchal translucency (NT) thickness, and maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A). METHODS Prospective combined screening for trisomy 21 was performed at 11 + 0 to 13 + 6 weeks in 56 893 singleton pregnancies, including 56 376 cases of euploid fetuses, 395 with trisomy 21 and 122 with trisomy 18… CONTINUE READING